Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Different homologous and heterologous vaccination regimens have been used for COVID-19. Here the authors show in a cohort analysis from Catalonia that heterologous vaccination with ChAdOx1 followed by BNT162b2 has better vaccine effectiveness than two doses of ChAdOx1.
Main Authors: | Eduardo Hermosilla, Ermengol Coma, Junqing Xie, Shuo Feng, Carmen Cabezas, Leonardo Méndez-Boo, Francesc Fina, Elisabet Ballo, Montserrat Martínez, Manuel Medina-Peralta, Josep Maria Argimon, Daniel Prieto-Alhambra |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-29301-9 |
Similar Items
-
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Hermosilla, E, et al.
Published: (2022) -
Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
by: Simone Barocci, et al.
Published: (2022-03-01) -
Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
by: Zhang, C, et al.
Published: (2023) -
Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
by: Cheng Zhang, et al.
Published: (2023-06-01) -
Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
by: Adam Berg, et al.
Published: (2021-10-01)